CML

conference reporter

by Jorge E. Cortes, MD

As seen at the 63rd ASH Annual Meeting and Exposition, treatment-free remission (TFR) is an important goal in chronic myeloid leukemia (CML). Facto......READ MORE

conference reporter

by Elias Jabbour, MD

Dose optimization may improve persistence with tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia (CP-CML). New data......READ MORE

conference reporter

by Elias Jabbour, MD

As reflected in data presented at the 63rd ASH Annual Meeting and Exposition, efforts are underway to refine current approaches to the management o......READ MORE

conference reporter

by Daniel J. DeAngelo, MD, PhD

At the 63rd ASH Annual Meeting and Exposition, patterns of care in chronic myeloid leukemia (CML) were explored using real-world analyses. The data......READ MORE

conference reporter

by Daniel J. DeAngelo, MD, PhD

At the 63rd ASH Annual Meeting and Exposition, several presentations on chronic-phase chronic myeloid leukemia (CP-CML) provided data that may add ......READ MORE